B

Bicara Therapeutics Inc
NASDAQ:BCAX

Watchlist Manager
Bicara Therapeutics Inc
NASDAQ:BCAX
Watchlist
Price: 10.44 USD -8.1% Market Closed
Market Cap: 569.4m USD
Section:
Profitability Summary
Profitability Summary
Past Growth
Margins
Return on Capital
Free Cash Flow
See Also

Profitability Summary

Bicara Therapeutics Inc's profitability score is 26/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

26/100
Profitability
Score
26/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less
0
Revenue
+0%
Mar 31, 2025 0
Dec 31, 2024 0
Sep 30, 2024 0
0
Operating Income
+0%
Mar 31, 2025 -124.2m
Dec 31, 2024 -82.4m
Sep 30, 2024 -95.6m
0
Net Income
+0%
Mar 31, 2025 -104.8m
Dec 31, 2024 -68m
Sep 30, 2024 -99m

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Bicara Therapeutics Inc

Revenue
0 USD
Operating Expenses
-124.2m USD
Operating Income
-124.2m USD
Other Expenses
19.3m USD
Net Income
-104.8m USD

Margins Comparison
Bicara Therapeutics Inc Competitors

Country Company Market Cap Operating
Margin 		Net
Margin
US
Bicara Therapeutics Inc
NASDAQ:BCAX
569.3m USD N/A N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
346.7B USD
30%
7%
US
Amgen Inc
NASDAQ:AMGN
153.2B USD
31%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
137.3B USD
38%
21%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
98.8B USD
39%
32%
AU
CSL Ltd
ASX:CSL
128.6B AUD
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.1B USD
29%
31%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.1B USD
-7%
-13%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
-33%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Bicara Therapeutics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Bicara Therapeutics Inc
NASDAQ:BCAX
569.3m USD
-23%
-22%
-27%
-938%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
346.7B USD
88%
3%
17%
20%
US
Amgen Inc
NASDAQ:AMGN
153.2B USD
99%
7%
16%
14%
US
Gilead Sciences Inc
NASDAQ:GILD
137.3B USD
33%
11%
25%
19%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
98.8B USD
23%
16%
24%
26%
AU
CSL Ltd
ASX:CSL
128.6B AUD
15%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.1B USD
15%
12%
12%
13%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.1B USD
-258%
-7%
-6%
-10%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less

See Also

Summary
BCAX intrinsic value, competitors valuation, and company profile.
DCF Valuation
BCAX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BCAX stock valuation using valuation multiples.
Wall Street Estimates
BCAX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BCAX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 273,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.